HPV status and favourable outcome in vulvar squamous cancer. Issue 5 (1st March 2017)

• Record Type: Journal Article
• Authors: Wakeham, Katie; Kavanagh, Kim; Cuschieri, Kate; Millan, David; Pollock, Kevin G.; Bell, Sarah; Burton, Kevin; Reed, Nicholas S; Graham, Sheila V
• Is Part Of: International journal of cancer. Volume 140:Issue 5(2017:Mar. 01)
• Page Start: 1134
• Page End: 1146
• Publication Date: 2017-03-01
• Subjects: HPV -- VIN -- vulvar cancer; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.30523
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : It is universally accepted that high‐risk human papillomavirus (HR‐HPV) is the cause of cervical dysplasia and cancer. More recently, it has been shown that HPV is also a marker of clinical outcome in oropharyngeal cancer. However, contemporary information is lacking on both the prevalence of HPV infection in vulvar cancer (VSCC), its precursor lesion, vulvar intraepithelial neoplasia (VIN) and the influence of HPV‐status on the prognosis of this malignancy. We have conducted a detailed population‐based study to examine rates of progression of VIN to VSCC, type‐specific HPV prevalence in vulvar disease and the influence of HPV status on clinical outcome in VSCC. We observed that the age at which women are diagnosed with VSCC is falling and there is a significant time gap between first diagnosis of VIN and progression to invasive disease. HR‐HPV infection was detected in 87% (97/112) cases of VIN and 52% cases (32/62) of VSCC. The presence of HR‐HPV in squamous intraepithelial lesion was associated with lower rates of progression to invasive cancer (hazard ratio, 0.22, p = 0.001). In the adjusted analysis, HR‐HPV was associated with improved progression‐free survival of VSCC compared to those with HPV negative tumours (hazard ratio, 0.32, p = 0.02). Abstract : What's new? High‐risk human papillomavirus (HR‐HPV) infection is associated with vulvar squamous cell cancer (VSCC) and its precursor, vulvar intraepithelial neoplasia, and is suspected to have a role in recent changes in VSCC epidemiology. Our study shows that in Scotland, where VSCC incidence has climbed markedly in the last three decades, median age of VSCC diagnosis was 64 years in 2014, compared to 76 years in 2001. Progression from VIN to VSCC was associated with a significant time gap. Moreover, hr‐HPV infection was common in VIN and was linked to reduced progression to VSCC and improved progression‐free survival of VSCC.